NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
0.809
+0.058 (7.78%)
Apr 28, 2026, 4:00 PM EDT - Market closed
NeuroSense Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 4.86 | 4.2 | 4.78 | 4.97 | 1.59 | |
| Research & Development | 6.23 | 5.7 | 7.27 | 5.59 | 1.39 | |
| Operating Expenses | 11.09 | 9.9 | 12.05 | 10.55 | 2.99 | |
| Operating Income | -11.09 | -9.9 | -12.05 | -10.55 | -2.99 | |
| Interest & Investment Income | 0.01 | 0 | 0.18 | 0.09 | - | |
| Currency Exchange Gain (Loss) | -0.05 | -0.05 | 0.02 | -0.02 | -0.03 | |
| Other Non Operating Income (Expenses) | -0.01 | -0.27 | 1.74 | -0.01 | -0.2 | |
| Pretax Income | -11.13 | -10.21 | -10.11 | -10.49 | -3.22 | |
| Net Income | -11.13 | -10.21 | -10.11 | -10.49 | -3.22 | |
| Net Income to Common | -11.13 | -10.21 | -10.11 | -10.49 | -3.22 | |
| Shares Outstanding (Basic) | 25 | 19 | 14 | 12 | 6 | |
| Shares Outstanding (Diluted) | 25 | 19 | 14 | 12 | 6 | |
| Shares Change (YoY) | 36.98% | 36.38% | 18.56% | 84.27% | 13.13% | |
| EPS (Basic) | -0.44 | -0.55 | -0.74 | -0.91 | -0.52 | |
| EPS (Diluted) | -0.44 | -0.55 | -0.74 | -0.91 | -0.52 | |
| Free Cash Flow | -7.68 | -10.14 | -8.38 | -7.69 | -1.56 | |
| Free Cash Flow Per Share | -0.30 | -0.55 | -0.61 | -0.67 | -0.25 | |
| EBITDA | -11.07 | -9.88 | -12.03 | -10.54 | -2.98 | |
| D&A For EBITDA | 0.02 | 0.02 | 0.02 | 0.01 | 0 | |
| EBIT | -11.09 | -9.9 | -12.05 | -10.55 | -2.99 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.